Coherus Oncology, Inc.: updates and filings

CHRSNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.39

November 19, 2026Market cap $58M

What Ploutos Investor adds for Coherus Oncology

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 14 fiscal years, from 2012
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 50% since Nov 9, 2026, when the 10-Q these figures come from was filed ($0.82 then, $0.41 on Nov 18, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 81 daysAround Feb 8, 2027 · for Q4 2026

last Nov 9, 2026next Feb 8, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 9, 2026 latest annualNov 9, 2026 latest quarterly
  • Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 9, 2026Results of operations
    Form8-K
  • Oct 29, 2026Regulation FD disclosure, other material events
    Form8-K
  • Aug 28, 2026Other material events
    Form8-K
  • Aug 17, 2026Regulation FD disclosure, other material events
    Form8-K
  • Aug 17, 2026Material agreement entered, material agreement ended, new material financial obligation
    Form8-K
  • Aug 5, 2026Shares registered for employees
    FormS-8
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Results of operations
    Form8-K
  • Jul 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jun 15, 2026Change of auditor
    Form8-K
  • Jun 1, 2026Shareholder vote
    Form8-K
  • May 28, 2026Additional annual meeting material
    FormDEFA14A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 11, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 11, 2026Results of operations
    Form8-K
  • May 11, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 5, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 29, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 20, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 20, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 14, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 9, 2026Preliminary proxy statement
    FormPRE 14A
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 23, 2011.

The full analysis

What do Coherus Oncology's filings show?

The filings are where every one of Coherus Oncology's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.